Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 11Terminated 5Recruiting 5Withdrawn 1Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 79Nasopharyngeal Carcinoma 51Uterine Cervical Neoplasms 44Lung Neoplasms 38Esophageal Neoplasms 32Head and Neck Neoplasms 28Esophageal Squamous Cell Carcinoma 28Squamous Cell Carcinoma of Head and Neck 22Stomach Neoplasms 20Breast Neoplasms 16Small Cell Lung Carcinoma 15Recurrence 12Neoplasm Metastasis 12Nasopharyngeal Neoplasms 12Carcinoma, Squamous Cell 10Ovarian Neoplasms 9Central Nervous System Neoplasms 9Neuroblastoma 8Lymphoma, Large B-Cell, Diffuse 8Pancreatic Neoplasms 7Lymphoma 7Hypopharyngeal Neoplasms 7Triple Negative Breast Neoplasms 6Oropharyngeal Neoplasms 6Neoplasms 6Biliary Tract Neoplasms 6Urinary Bladder Neoplasms 5Lymphoma, Non-Hodgkin 5Lymphoma, Large-Cell, Immunoblastic 5Lymphoma, Follicular 5

Interventions

Fluorouracil 3durvalumab 2ceralasertib 2Oxaliplatin 2Leucovorin 2Gemcitabine 21-phenyl-3,3-dimethyltriazene 2pembrolizumab 1olaparib 1Stents 1Relaxation Therapy 1Radiotherapy 1Radiofrequency Ablation 1Photochemotherapy 1Nutritional Status 1Long-Term Synaptic Depression 1Lasers 1Irinotecan 1Filgrastim 1Exercise 1Enteral Nutrition 1Cyclooxygenase 2 Inhibitors 1Cisplatin 1Celecoxib 1CGX1321 1Biopsy, Fine-Needle 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Bile Duct Neoplasms × Cisplatin × Clear all
NCT03086993 2022-03-24

Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma

Delcath Systems Inc.

Phase 2/3 Unknown
295 enrolled
Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡